Author

H. Al-Ahmadie

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin.

Combination therapy with enfortumab vedotin, a Nectin-4-targeted antibody-drug conjugate, and pembrolizumab, an anti-PD1 antibody, recently supplanted platinum-based chemotherapy as standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating...

James A. Rodrigues, H. Al-Ahmadie, D. Aggen et al. · Clinical Cancer Research · 0 citations

Open access Oct 2026

Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.

More than half of patients had high pretreatment tumor PD-L1 expression, and there was no significant association between PD-L1 status and ORR, PFS, or OS with any first-line therapy, although definitive conclusions cannot be made because of the limited sample size.

P. Grivas, P. Agarwal, H. Al-Ahmadie et al. · Targeted oncology · 0 citations